YAN LU^1,2,#, KANG WANG^3,#, YUANHONG PENG^3,4, MENG CHEN⁵, LIN ZHONG^3,4, LUJI HUANG^3,4, FU CHENG^3,4, XINDAN SHENG^4,6, XIN YANG^4,6, MANZHAO OUYANG^3,4, GEORGE A. CALIN^5,*, ZHIWEI HE^1,*

Oncology Research, Vol.33, No.1, pp. 103-121, 2025, DOI:10.32604/or.2024.057472 - 20 December 2024

Abstract Background: Immune checkpoint inhibitors play an important role in the treatment of solid tumors, but the currently used immune checkpoint inhibitors targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) show limited clinical efficacy in many breast cancers. B7H3 has been widely reported as an immunosuppressive molecule, but its immunological function in breast cancer patients remains unclear. Methods: We analyzed the expression of B7H3 in breast cancer samples using data from the Cancer Genome Atlas Program (TCGA) and the Gene Expression Omnibus (GEO) databases. MicroRNAs were selected using the… More >

WEI ZHANG^1,3,#, WEICHENG WANG^1,#, RUI WANG¹, XIAO HAN¹, LIJUN ZHU¹, WENJIE GUO^2,*, YANHONG GU^1,*

Oncology Research, Vol.33, No.1, pp. 225-234, 2025, DOI:10.32604/or.2024.050047 - 20 December 2024

Abstract Background: As a novel blocker of vascular endothelial growth factor receptor (VEGFR), fruquintinib has been approved for treating colorectal cancer (CRC). However, its dosage and therapeutic efficacy are limited by its widespread adverse reactions. Venetoclax, recognized as the initial inhibitor of B-cell lymphoma protein 2 (BCL2), has shown potential in boosting the effectiveness of immunotherapy against CRC. This study investigated the efficacy and mechanisms of fruquintinib combined with venetoclax in treating CRC. Methods and Materials: We developed a colon cancer mouse model with the CT26 colon cell line to demonstrate fruquintinib and venetoclax’s efficacy against tumors.… More > Graphic Abstract

RYUL KIM^1,#, JOO KYUNG PARK^2,#, MINSUK KWON³, MINAE AN⁴, JUNG YONG HONG¹, JOON OH PARK¹, SUNG HEE LIM^1,*, SEUNG TAE KIM^1,*

Oncology Research, Vol.33, No.1, pp. 57-65, 2025, DOI:10.32604/or.2024.049054 - 20 December 2024

Abstract Background: Immune checkpoint inhibitors (ICIs) are effective in a subset of patients with metastatic solid tumors. However, the patients who would benefit most from ICIs in biliary tract cancer (BTC) are still controversial. Materials and methods: We molecularly characterized tissues and blood from 32 patients with metastatic BTC treated with the ICI pembrolizumab as second-line therapy. Results: All patients had microsatellite stable (MSS) type tumors. Three of the 32 patients achieved partial response (PR), with an objective response rate (ORR) of 9.4% (95% confidence interval [CI], 2.0–25.2) and nine showed stable disease (SD), exhibiting a disease… More >

Evangelia Vlachou¹, Burles Avner Johnson 3rd^1,2, Elizabeth Guancial³, Kara A. Lombardo^1,2,4, Jean Hoffman-Censits^1,2

Canadian Journal of Urology, Vol.31, No.3, pp. 11875-11879, 2024

Abstract Introduction: Immune checkpoint inhibitors (ICIs) are approved for advanced urothelial cancer alone and as first line in combination with enfortumab vedotin. Platinum based chemotherapy which is another frontline choice is often not a treatment option for older patients due to comorbidities that increase with age. Despite ICIs being better tolerated compared to traditional chemotherapy little is known about their efficacy and toxicity in patients ≥ 90 years due to the rarity of this population in clinical trials. Our objective was to analyze the efficacy and toxicity of immune checkpoint inhibitors in patients ≥ 90 years.
Materials and… More >

Andrew S. Iskandar, Kevin K. Zarrabi, William J. Tester

Canadian Journal of Urology, Vol.31, No.4, pp. 11921-11930, 2024

Abstract Introduction: Renal cell carcinoma is as the most prevalent form of kidney cancer, with the clear cell subtype comprising approximately 75% of cases. The identification of predictive and prognostic biomarkers has emerged as a crucial area of research within the field. Despite advancements in treatment, metastatic renal cell carcinoma presents formidable challenges, with survival rates heavily dependent upon the optimal choice of treatment.
Materials and methods: This review summarizes the current literature regarding the prognostic and predictive value of biomarkers in patients with renal cell carcinoma. We conducted a comprehensive literature search to identify studies that reference… More >

Erdong Shen¹, Ting Pan¹, Pan Guo¹, Ke Chen¹, Rui Xu¹, Mei Yang¹, Dahe Zhan¹, Fang Fang¹, Qinghui Wu^1,*, Jianbing Hu^1,*

The International Conference on Computational & Experimental Engineering and Sciences, Vol.30, No.4, pp. 1-3, 2024, DOI:10.32604/icces.2024.012772

Abstract Objective
This study investigates the synergistic effects of a novel multifunctional nanoparticle on gastric cancer treatment through photothermal therapy, chemotherapy, and immunotherapy.

Method
Synthesize hollow mesoporous Prussian blue nanoparticles and load them with luteolin. Use exosomes to encapsulate the nanoparticles and modify the surface of the targeted peptide GX1. Detect the morphology of nanoparticles using a nanoparticle size analyzer and transmission electron microscopy. Use Coomassie Brilliant Blue to detect the effect of extracellular vesicle encapsulation. Detect the thermal conversion efficiency of nanoparticles under specific laser irradiation through infrared and ultraviolet spectroscopy, as well as the release rate… More >

JYOTHI B. NAIR^1,2, ANU MARY JOSEPH³, SANOOP P.⁴, MANU M. JOSEPH^5,*

BIOCELL, Vol.48, No.11, pp. 1579-1602, 2024, DOI:10.32604/biocell.2024.054879 - 07 November 2024

Abstract Nanoparticles represent a heterogeneous collection of materials, whether natural or synthetic, with dimensions aligning in the nanoscale. Because of their intense manifestation with the immune system, they can be harvested for numerous bio-medical and biotechnological advancements mainly in cancer treatment. This review article aims to scrutinize various types of nanoparticles that interact differently with immune cells like macrophages, dendritic cells, T lymphocytes, and natural killer (NK) cells. It also underscores the importance of knowing how nanoparticles influence immune cell functions, such as the production of cytokines and the presentation of antigens which are crucial for… More >

SULING XU¹, XIAO LI², WENXUE MA^3,*

Oncology Research, Vol.32, No.11, pp. 1701-1708, 2024, DOI:10.32604/or.2024.055161 - 16 October 2024

Abstract The environment surrounding a tumor, known as the tumor microenvironment (TME), plays a role in how cancer progresses and responds to treatment. It poses both challenges and opportunities for improving cancer therapy. Recent progress in understanding the TME complexity and diversity has led to approaches for treating cancer. This perspective discusses the strategies for targeting the TME, such as adjusting networks using extracellular vesicles to deliver drugs and enhancing immune checkpoint inhibitors (ICIS) through combined treatments. Furthermore, it highlights adoptive cell transfer (ACT) therapies as an option for tumors. By studying how components of the More >

SHUBHRA CHANDRA^1,2, JENNIFER C. WILSON^1,2, DAVID GOOD³, MING Q. WEI^1,2,*

Oncology Research, Vol.32, No.10, pp. 1543-1564, 2024, DOI:10.32604/or.2024.043987 - 18 September 2024

Abstract The advent of RNA therapy, particularly through the development of mRNA cancer vaccines, has ushered in a new era in the field of oncology. This article provides a concise overview of the key principles, recent advancements, and potential implications of mRNA cancer vaccines as a groundbreaking modality in cancer treatment. mRNA cancer vaccines represent a revolutionary approach to combatting cancer by leveraging the body’s innate immune system. These vaccines are designed to deliver specific mRNA sequences encoding cancer-associated antigens, prompting the immune system to recognize and mount a targeted response against malignant cells. This personalized… More > Graphic Abstract

ZHENGYI WANG^1,*, LIANG ZHOU¹, XIAOYING WU²

Oncology Research, Vol.32, No.9, pp. 1479-1516, 2024, DOI:10.32604/or.2024.048564 - 23 August 2024

Abstract Chimeric antigen receptor T-cesll therapy (CAR–T) has achieved groundbreaking advancements in clinical application, ushering in a new era for innovative cancer treatment. However, the challenges associated with implementing this novel targeted cell therapy are increasingly significant. Particularly in the clinical management of solid tumors, obstacles such as the immunosuppressive effects of the tumor microenvironment, limited local tumor infiltration capability of CAR–T cells, heterogeneity of tumor targeting antigens, uncertainties surrounding CAR–T quality, control, and clinical adverse reactions have contributed to increased drug resistance and decreased compliance in tumor therapy. These factors have significantly impeded the widespread More > Graphic Abstract